Hansa Biopharma: Q3 Launch and Genetic exploratory progress
Research Note
2022-10-20
08:59
Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.
JU
Johan Unnerus
Disclosures and disclaimers